Hypertension, smoking, and preexistence of multiple cardiac risk factors correlate with carfilzomib-induced cardiovascular adverse events in a racially diverse population

BACKGROUND: Use of the proteasome inhibitor carfilzomib has become a standard of care in patients with relapsed/refractory multiple myeloma. An association between carfilzomib and cardiovascular adverse events has been well documented, but this had not been investigated in a racially diverse populat...

Descripción completa

Detalles Bibliográficos
Autores principales: Doran, Stacey, Mysore, Manu, Kassaian, Seyed Ebrahim, Kotloff, Ethan, Kamangar, Farin, Emadi, Ashkan, Apata, Jummai, Barr, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285053/
https://www.ncbi.nlm.nih.gov/pubmed/37363095
http://dx.doi.org/10.3389/fcvm.2023.1129943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285053/
https://www.ncbi.nlm.nih.gov/pubmed/37363095
http://dx.doi.org/10.3389/fcvm.2023.1129943

Ejemplares similares